{
    "clinical_study": {
        "@rank": "10104", 
        "acronym": "LOWER", 
        "arm_group": {
            "arm_group_label": "Lomitapide", 
            "description": "Lomitapide as prescribed by Physician."
        }, 
        "brief_summary": {
            "textblock": "This global product exposure registry is a multicentre, long-term, prospective,\n      observational cohort study (exposure registry), designed to evaluate the long term safety\n      and effectiveness of lomitapide."
        }, 
        "brief_title": "LOWER: Lomitapide Observational Worldwide Evaluation Registry", 
        "completion_date": {
            "#text": "September 2028", 
            "@type": "Anticipated"
        }, 
        "condition": "Homozygous Familial Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": [
                "Hypercholesterolemia", 
                "Hyperlipoproteinemia Type II"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the occurrence of adverse events of special interest, long term effectiveness of\n      lomitapide, and to evaluate whether prescribers of lomitapide are following screening and\n      monitoring recommendations as specified in product labeling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (age \u226518 years) who meet one of the following two criteria:\n\n        Initiating treatment with lomitapide at the time of registry enrolment, or initiated\n        treatment with lomitapide within 15 months prior to enrolment into the registry and after\n        lomitapide commercial availability in the country.\n\n          -  Patients who have the ability to understand the requirements of the study   and\n             provide written informed consent to comply with the study data collection procedures.\n\n        Exclusion Criteria:\n\n          -  Patients who are receiving lomitapide in clinical trials\n\n          -  Patients receiving an investigational agent, defined as any drug or biologic agent\n             other than lomitapide that has not received MA in the country of participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients treated with lomitapide who agree to participate in the study."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02135705", 
            "org_study_id": "AEGR-733-025"
        }, 
        "intervention": {
            "arm_group_label": "Lomitapide", 
            "description": "As prescribed by Physician.", 
            "intervention_name": "Lomitapide", 
            "intervention_type": "Drug", 
            "other_name": [
                "Juxtapid", 
                "Lojuxta"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sterling Heights", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48314"
                }, 
                "name": "Complete Family Care"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "LOWER: Lomitapide Observational Worldwide Evaluation Registry", 
        "overall_official": {
            "affiliation": "Aegerion Pharmaceuticals, Inc.", 
            "last_name": "Helen Phillips, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2028", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to evaluate the occurrence of hepatic abnormalities", 
            "measure": "Hepatic Abnormalities", 
            "safety_issue": "Yes", 
            "time_frame": "patients will be followed for 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02135705"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "to evaluate the occurrence of GI events", 
                "measure": "Gastrointestinal (GI) Events", 
                "safety_issue": "Yes", 
                "time_frame": "patients will be followed for 10 years"
            }, 
            {
                "description": "to evaluate any occurrence of tumors (small bowel, hepatic, colorectal or pancreatic)", 
                "measure": "Tumors", 
                "safety_issue": "Yes", 
                "time_frame": "patients will be followed for 10 years"
            }, 
            {
                "description": "to evaluate the occurrence of events associated with coagulopathy (abnormal bleeding, cerebral haemorrhage or GI bleeding)", 
                "measure": "Events associated with coagulopathy", 
                "safety_issue": "Yes", 
                "time_frame": "patients will be followed for 10 years"
            }
        ], 
        "source": "Aegerion Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aegerion Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "10 Years", 
        "verification_date": "May 2014"
    }
}